Please login to the form below

Not currently logged in
Email:
Password:

Gaucher disease

This page shows the latest Gaucher disease news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • FDA changes its mind on 23andMe's genetic testing kits FDA changes its mind on 23andMe's genetic testing kits

    Along with Alzheimer's and Parkinson's, the new Genetic Health Risk (GHR) test covers coeliac disease, alpha-1 antitrypsin deficiency, early onset primary dystonia, Factor XI deficiency, type 1 Gaucher ... tests. The exemption will not however include

  • Langland and CAHG take top prizes at Best of Health Awards Langland and CAHG take top prizes at Best of Health Awards

    Healthcare Professional - Direct Marketing &Promotional Communications Individual. 'Hard to see, but easy to find - Rare Disease Awareness Campaign for Gaucher Disease' for Shire Pharmaceuticals, by bmore Creative .

  • Shire picks winner for Gaucher film contest Shire picks winner for Gaucher film contest

    A Shire spokesperson told PMLiVE: “We are hoping the videos are seen by the Gaucher community, and also by the general public, to raise awareness of Gaucher disease.”. ... At Shire, we are committed to working with the community to raise awareness of

  • Patient survey finds pharma falls short on drug pricing Patient survey finds pharma falls short on drug pricing

    PatientView highlights that the company ranked number one for corporate reputation - Sanofi - has a strong track record in developing innovative medicines for diseases with unmet needs, such as Gaucher disease and

  • Shire rumoured to be pursuing Actelion Shire rumoured to be pursuing Actelion

    Last month, Alexion unveiled an $8.4bn agreement to buy rare disease specialist Synageva, while Shire itself agreed to buy NPS for $5.2bn earlier this year. ... Buying Actelion would give Shire a portfolio of drugs to treat pulmonary artery hypertension

More from news
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year. ... BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    in rare diseases such as Gaucher disease and Cushing’s disease and in hepatitis C. She also has experience in cardiovascular disease, haematology and infectious diseases. ... emotive is an award-winning healthcare communications agency working

  • Making good practice common practice in rare disease

    2016 – Researchers found that people with Gaucher disease ascribed more importance to fatigue than to other disease parameters, while their doctors put greater weight on objective measures of visceral and hematologic ... symptoms. Literature suggests

  • Focus on Rare Diseases

    As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond. ... Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease,

  • Can rare diseases be a viable option for the pharma industry?

    An example of this would be Gaucher’s disease, which has 3 specific sub-types of patients requiring dynamic modeling of the data from patient registries over a 60 year time ... Epiomic Patient Segmentation Database, Metabolic Disorders Category,

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics